New Delhi, Feb 28 (IANS) Only human trials will help understand the efficacy of the new Rs 100 pill developed to prevent recurrence of cancer, said doctors on Wednesday.
According to a report by NDTV, researchers at the Tata Memorial Centre (TMC) in Mumbai claimed to have discovered a treatment to prevent relapse of cancer that would cost only Rs 100.
The study on mice showed that the pill, named ‘R+Cu’, containing a pro-oxidant combination of resveratrol and copper, generated oxygen radicals in the stomach to curb cancer recurrence.
The experimental mice study “is not a substitute for established treatments, which continue to result in cures in a substantial proportion of cancer patients,” Dr Shyam Aggarwal, Chairman, Department of Medical Oncology, at Sir Ganga Ram Hospital told IANS.
In a post on X, Dr. Rajeev Jayadevan, Co-Chairman National IMA Covid Task Force called it “an exaggerated claim”. While calling the research “interesting, praiseworthy”, he said it cannot be seen as “cancer cure.”
Dr Shyam Aggarwal explained that the research shows the effect of cell-free chromatin (fragments of chromosomes released from cancer cells after chemotherapy) on normal tissues causing a cascade of inflammation leading to side effects such as mucositis, low blood counts, etc.
“Use of a combination of copper and resveratrol (a commercially-available nutraceutical) has been shown to degrade circulating cell-free chromatin, leading to reduction of toxicity in some human studies. Other human studies are underway,” he said.
The study claims that the pill can halve the side effects caused by chemotherapy, while also reducing the odds of getting cancer by 30 per cent.
The researchers “used a pro-oxidant combination of copper and resveratrol (found in peanuts, cocoa, grapes) known to damage DNA by generating oxygen radicals,” Dr. Rajeev Jayadevan wrote in his post on X.
“Whether this will translate into real world outcomes for people with cancer (beyond mice), what toxicities could occur from its pro-oxidant, DNA-damaging effect, is yet to be determined,” he said.
However, Dr. Rahul Bhargava, Principal Director & Chief BMT, Fortis Memorial Research Institute, Gurugram, called it “a great breakthrough in the field of medical research. Indian researchers are creating history. If the drug works, it will be a great benefit for cancer patients.”
“The tablet is promising and shows potential to be effective, but human trials are yet to be completed, which could take about five years,” he told IANS.
The tablet is awaiting approval from the Food Safety and Standards Authority of India (FSSAI) and is expected to be available in the market by June-July.
–IANS
rvt/rad
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by TodayIndia.news and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of TodayIndia.news We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, TodayIndia.news takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
